Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;66(5):e271-e278.
doi: 10.1111/ajd.14523. Epub 2025 May 16.

Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid

Bronte Jeffrey  1   2   3 , Mark Schifter  4   5 , Elizabeth Arena  5 , Emily Sullivan  1   2   3   4 , Stephanie Rose  5 , David Joo  5 , David Campbell  3 , Suzanne Culican  3 , David McDonald  3 , Ming Wei Lin  1   3   4   6
Affiliations

Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid

Bronte Jeffrey et al. Australas J Dermatol. 2025 Aug.

Abstract

Background: Mucous membrane pemphigoid (MMP) has a broad range of clinical manifestations, from relatively benign self-limiting oral lesions to significant scarring (cicatrizing) of the oral, nasal and ocular tissues with severe functional impairment and morbidity. European Guidelines recommend rituximab as only second- or third-line therapy, based on the extent/severity of the disease; however, there are no established clinical or serological markers that are predictive of severe disease warranting the use of agents such as rituximab.

Methods: Retrospective cross-sectional cohort study of patients who met the following criteria: (1) biopsy confirmed MMP; (2) required a steroid-sparing immunosuppressant therapy, that is, mycophenolate and/or rituximab and (3) at least 6 months of clinical monitoring. The primary end point was complete or partial remission.

Results: Of the 45 patients who met the criteria, 12 (27%) had sustained remission with mycophenolate. Thirty-three (73%) patients had either relapsed or were refractory to mycophenolate and, therefore, were treated with rituximab. Of those who received rituximab, 97% achieved a complete remission after a single course (1 g given intravenously on Days 1 and 14), but 24% needed repeat treatment. The detection rates of key circulating antibodies, namely skin basement membrane antibodies (SBMA), BP180/230, collagen VII and laminin 332, were low and did not identify those patients refractory to mycophenolate. Adverse reactions, including infectious complications, were minimal in both patient groups.

Conclusion: In our study of mostly localised mucosal MMP patients, there was an excellent response to a single course of treatment with rituximab, with durable remission and no major adverse complications.

Keywords: biomarkers; bullous; oral; pemphigoid; rituximab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Schematic diagram of the dermoepidermal junction. Only molecules that are targeted by autoantibodies in pemphigoid diseases are shown (modified from Schmidt and Zillikens with permission) [2].
FIGURE 2
FIGURE 2
Oral immunobullous clinic workflow.
FIGURE 3
FIGURE 3
Study and patient flow. CS, corticosteroid; IS, immunosuppression; MMF, mycophenolate.
See this image and copyright information in PMC

References

    1. Du G., Patzelt S., van Beek N., and Schmidt E., “Mucous Membrane Pemphigoid,” Autoimmunity Reviews 21, no. 4 (2022): 103036. - PubMed
    1. Schmidt E. and Zillikens D., “Pemphigoid Diseases,” Lancet 381, no. 9863 (2013): 320–332. - PubMed
    1. Lazarova Z., Yee C., Darling T., Briggaman R. A., and Yancey K. B., “Passive Transfer of Anti‐Laminin 5 Antibodies Induces Subepidermal Blisters in Neonatal Mice,” Journal of Clinical Investigation 98, no. 7 (1996): 1509–1518. - PMC - PubMed
    1. Bhol K., Colon J., and Ahmed A., “Autoantibody in Mucous Membrane Pemphigoid Binds to an Intracellular Epitope on Human β4 Integrin and Causes Basement Membrane Zone Separation in Oral Mucosa in an Organ Culture Model,” Journal of Investigative Dermatology 120 (2003): 710–720. - PubMed
    1. Kamaguchi M., Iwata H., Ujiie H., et al., “High Expression of Collagen XVII Compensates for Its Depletion Induced by Pemphigoid IgG in the Oral Mucosa,” Journal of Investigative Dermatology 138, no. 8 (2018): 1707–1715. - PubMed